Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies

Cancer Research

Volumn 77, Issue 10, 2017, Pages 2686-2698

  Rios Doria, Jonathan ^a   Harper, Jay ^a   Rothstein, Raymond ^a   Wetzel, Leslie ^a   Chesebrough, Jon ^a   Marrero, Allison ^a   Chen, Cui ^a   Strout, Patrick ^a   Mulgrew, Kathy ^a   McGlinchey, Kelly ^a   Fleming, Ryan ^a   Bezabeh, Binyam ^a   Meekin, John ^a   Stewart, David ^a,b   Kennedy, Maureen ^a   Martin, Philip ^a   Buchanan, Andrew ^a   Dimasi, Nazzareno ^a   Michelotti, Emil ^a   Hollingsworth, Robert ^a  

^a MEDIMMUNE   (United States)

^b GlycoMimetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EPHRIN A2 PYRROLOBENZODIAZEPINE CONJUGATE; EPHRIN A2 TUBULYSIN CONJUGATE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR LIGAND FUSION PROTEIN; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY OX86; OX40 LIGAND FUSION PROTEIN; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; CANCER VACCINE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PYRROLE DERIVATIVE; PYRROLO(2,1-C)(1,4)BENZODIAZEPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; EX VIVO STUDY; FEMALE; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; T CELL DEPLETION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; METABOLISM; RAT; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; BIOMARKERS; CANCER VACCINES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; PROGRAMMED CELL DEATH 1 RECEPTOR; PYRROLES; RATS; T-LYMPHOCYTE SUBSETS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85018433781     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-2854     Document Type: Article

References (47)

1. Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013;94:41-53.
2. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
3. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 2016;13:394.
4. Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment.Nat Rev Clin Oncol 2016;13:143-58.
5. Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 2016;15:235-47.
6. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
7. Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014;3:e955691.
8. Rios-Doria J, Durham N, Wetzel L, Rothstein R, Chesebrough J, Holoweckyj N, et al. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models. Neoplasia 2015;17:661-70.
9. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012;11:215-33.
10. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010;29:482-91.
11. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death.Nat Med 2007;13:54-61.
12. Liu L, Mayes PA, Eastman S, ShiH, Yadavilli S, Zhang T, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 2015;21:1639-51.
13. Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 2015;7:279ra41.
14. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12:237-51.
15. Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A 2015;112:E966-72.
16. Gerber HP, Sapra P, Loganzo F, May C. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol 2016;102:1-6.
17. Schumacher D, Hackenberger CP, Leonhardt H, Helma J. Current status: site-specific antibody drug conjugates. J Clin Immunol 2016;36Suppl 1:100-7.
18. Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol 2016;17:e254-62.
19. Muller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res 2014;2:741-55.
20. Muller P, Martin K, Theurich S, von Bergwelt-Baildon M, Zippelius A. Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity. Oncoimmunology 2014;3:e954460.
21. Muller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med 2015;7:315ra188.
22. Hartley JA. The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs 2011;20:733-44.
23. Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 2016;29:117-29.
24. Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 2013;24:1256-63.
25. Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cellsin vivo. Sci Transl Med 2015;7:302ra136.
26. al-Shamkhani A, Birkeland ML, Puklavec M, Brown MH, James W, Barclay AN. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur J Immunol 1996;26:1695-9.
27. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol 2014; 92:475-80.
28. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206:1717-25.
29. Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growthin vivo. Cancer Res 2008;68:9367-74.
30. Lelliott CJ, Ahnmark A, Admyre T, Ahlstedt I, Irving L, Keyes F, et al. Monoclonal antibody targeting of fibroblast growth factor receptor 1c ameliorates obesity and glucose intolerance via central mechanisms. PLoS One 2014;9:e112109.
31. Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H.A new bliss independence model to analyze drug combination data. J Biomol Screen 2014;19:817-21.
32. Rice J, Buchan S, Stevenson FK. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. J Immunol 2002;169:3908-13.
33. Schaer DA, Murphy JT, Wolchok JD. Modulation of GITR for cancer immunotherapy. Curr Opin Immunol 2012;24:217-24.
34. Teng MW, Swann JB, von Scheidt B, Sharkey J, Zerafa N, McLaughlin N, et al. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res 2010;70:2665-74.
35. Coe D, Begom S, Addey C, White M, Dyson J, Chai JG. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 2010;59: 1367-77.
36. Schaer DA, Budhu S, Liu C, Bryson C, Malandro N, Cohen A, et al. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res 2013;1: 320-31.
37. Hu P, Arias RS, Sadun RE, Nien YC, Zhang N, Sabzevari H, et al. Construction and preclinical characterization of fc-mGITRL for the immunotherapy of cancer. Clin Cancer Res 2008;14:579-88.
38. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005;202:1691-701.
39. Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS- 8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 2016;22:5097-108.
40. Konermann A, Deschner J, Allam JP, Novak N, Winter J, Baader SL, et al. Antigen-presenting cell marker expression and phagocytotic activity in periodontal ligament cells. J Oral Pathol Med 2012;41:340-7.
41. McLellan AD, Starling GC, Williams LA, Hock BD, Hart DN. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule. Eur J Immunol 1995;25:2064-8.
42. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid- derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16:4583-94.
43. Lee JM, Seo JH, KimYJ, Kim YS, Ko HJ, Kang CY. The restoration of myeloidderived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment. Int J Cancer 2012;131:741-51.
44. Holmgaard RB, Brachfeld A, Gasmi B, Jones DR, Mattar M, Doman T, et al. Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. Oncoimmunology 2016;5: e1151595.
45. Gorovits B, Krinos-Fiorotti C. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake. Cancer Immunol Immunother 2013;62:217-23.
46. Hinrichs MJ, Dixit R. Antibody drug conjugates: nonclinical safety considerations. AAPS J 2015;17:1055-64.
47. Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 2016;8:659-71.